

ORIGINAL ARTICLE

The role of topical probiotics on wound healing: A review of animal and human studies

Rebecca Knackstedt¹  | Thomas Knackstedt² | James Gatherwright³

¹Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio

²Department of Dermatology, MetroHealth, Cleveland, Ohio

³Division of Plastic Surgery, MetroHealth, Cleveland, Ohio

Correspondence

Rebecca Knackstedt, MD, PhD, Cleveland Clinic, Mail Code A60, 2049 E. 100th Street, Cleveland, OH 44195.
Email: knacksr@ccf.org

Abstract

Pathogenic, opportunistic, and commensal bacterial coexist in the intestinal tract, and imbalances among these strains have been linked to systemic inflammation and a variety of disease states. Similarly, human skin plays an important role as an interface between the body and the environment with an estimated 1 billion microbes per square centimetres. Skin microbiome fluctuations that cause increases in pathologic bacteria, either because of individual and/or environmental factors, can lead to disease states at the skin level ranging from inflammatory conditions to infections. As wounds are inherently associated with perturbations in the local microflora due to injury and activation of the immune responses, the addition of topical probiotics could be a means to prevent infection, regulate inflammation, and potentially augment healing. The goal of this review is to analyse the impact the skin microbiome has on cutaneous wound healing with a focus on developing proposed treatment algorithms and support for their therapeutic potential.

KEYWORDS

acute wound, biofilm, chronic wound, probiotics

1 | INTRODUCTION

The human gastrointestinal tract is home to an estimated 300 to 500 bacterial species, and the total number of bacteria in the gut is projected to be 10 times greater than the number of cells in the body.¹ Pathogenic, opportunistic, and commensal bacteria coexist in the intestinal tract, and imbalances among these strains have been linked to systemic inflammation and a variety of disease states.² Virulent bacterial species include *Escherichia coli*, *Pseudomonas aeruginosa*, and *Enterococcus faecalis*,³⁻⁵ while commensal strains include *Lactobacillus* and *Bifidobacterium*. Each individual hosts a unique biome that fluctuates daily based on diet, exercise, medications, surgical procedures, and stress.³⁻¹¹ Therefore, the gastrointestinal tract can be thought of as a constantly evolving and changing interaction between the external environment and one's internal milieu.

Similarly, human skin plays an important role as an interface between the body and the environment with an estimated 1 billion microbes per square centimetre.¹² The skin microbiome functions to promote local homeostasis by influencing the immune response.¹³⁻¹⁷ Analogous skin microbiome fluctuations that cause increases in pathologic bacteria, either because of individual and/or environmental factors, can lead to disease states at the skin level, ranging from inflammatory conditions to infections.^{3-11,18-20}

Therefore, any interventions that promote healthy bacteria and decrease pathologic bacteria should aid in wound healing. To that end, probiotics have shown efficacy in promoting cutaneous wound healing, regulating glucose homeostasis, decreasing inflammation, and improving various skin conditions.²¹⁻³¹ A meta-analysis published in 2017 analysed six articles that explored

topical and oral probiotics in animal models with cutaneous wounds. While they concluded that probiotics could be a useful treatment for cutaneous wounds, there was significant variability among the studies.³² As wounds are inherently associated with perturbations in the local microflora because of injury and activation of the immune responses, the addition of topical probiotics could be a means to prevent infection, regulate inflammation, and potentially augment healing. The goal of this review is to analyse the impact the skin microbiome has on cutaneous wound healing with a focus on developing proposed treatment algorithms and support for their therapeutic potential.

2 | WOUND HEALING AND TOPICAL PROBIOTIC: GENERAL STUDIES

Probiotics have demonstrated the ability in multiple human and animal models to improve wound-healing efficacy.³³⁻⁴² Probiotics of investigation have included *L. plantarum*, kefir, *L. fermentum*, and *S. cerevisiae* in thermal injury models, infected and non-infected wounds, and diabetic ulcers. In these studies, the mechanism of action was typically not explored, but topical probiotic treatment resulted in improved healing as demonstrated by increased granulation tissue deposition, improved collagen concentration, and stimulation of angiogenesis.³³⁻⁴² However, not all models demonstrated an improvement in topical wound healing with probiotics³³⁻⁴⁴ (Tables 1 and 2).

3 | WOUND HEALING AND TOPICAL PROBIOTIC: PREVENTION OF INFECTION

To permit successful wound healing, bacterial counts must be below 10^5 organisms per gram of tissue and void of any beta-haemolytic *Streptococcus* bacteria.⁴⁵ As bacteria and exotoxins lead to local inflammation, they can interfere with epithelialization, contraction and collagen deposition and can suppresses macrophage-regulated fibroblast proliferation.⁴⁶ Thus, the prevention and treatment of wound infections is a crucial aspect of wound healing.

There are numerous options to prevent wound infections, such as silver dressings, iodine, and antibacterial skin products. While silver products have been used for over 2000 years because of their putative antimicrobial activity, a recent review found no convincing evidence that they have any effect on wound healing.⁴⁷⁻⁵⁰ Iodine

Key messages

- as wounds are inherently associated with perturbations in the local microflora because of injury and activation of the immune responses, the addition of topical probiotics could be a means to prevent infection, regulate inflammation, and potentially augment healing
- topical probiotics have demonstrated efficacy in multiple human and animal models at augmenting numerous aspects of wound healing, but there are many unanswered questions; there is marked heterogeneity regarding the insult investigated, type and dosing regimen of the probiotic utilised, and a lack of standardised outcome measures
- the goal of this review is to analyse the impact the skin microbiome has on cutaneous wound healing with a focus on developing proposed treatment algorithms and support for their therapeutic potential

has been linked with cellular toxicity,⁵¹ and topical antibiotics can lead to antibiotic resistance and contact dermatitis.^{52,53} In contrast, topical probiotics are rarely associated with any systemic side effects and still retain their broad-spectrum antimicrobial activity. Kefir, a cultured probiotic beverage, has also shown to have topical antimicrobial activity against *Salmonella*, *Helicobacter*, *Shigella* and *Staphylococcus*, and *E. coli*.⁵⁴

The mechanism of action by which probiotics are able to induce this antimicrobial effect has not yet been fully elucidated but is likely multifactorial. They produce exopolysaccharides that have immunostimulatory activity and are able to activate macrophages and lymphocytes.^{55,56} In addition, probiotics have been shown to decrease the concentration of pathogenic bacteria via species-specific antagonism.^{18-20,57,58} Another antimicrobial mechanism of action of probiotics is through the regulation of antimicrobial peptides (AMPs). AMPs are produced by a variety of cells (eg, mast cells, epithelial cells, and adipocytes) and help to maintain the integrity of the skin. They act to modulate the skin microflora via different mechanisms, leading to improved skin integrity, decreased inflammation, and are preventive against biofilm development. They have also been shown to augment cell proliferation and angiogenesis and, in combination with the aforementioned effects, create a

TABLE 1 Probiotics in wound healing: Animal studies

Author	Year	Treatment arms	Probiotic used	Dose	Finding
Valdez	2005	1. Burn 2. Burn/saline 3. Burn/PB	<i>L. plantarum</i>	200–300 CFU once	PB decreased BT improved tissue repair, phagocytosis, apoptosis
Rodrigues	2005	1. Punch with saline 2. Punch with neomycin-clobetasol 3. Punch with kefir	Kefir with <i>Leuconostoc</i> spp., <i>Lactobacillus lactis</i> , <i>Acetobacter</i> spp., <i>Saccharomyces cerevisiae</i> , <i>Kluyveromyces marxianus</i> , and <i>K. lactis</i>	Unknown	Kefir enhanced wound healing measured by size and histology with improved granulation and neovascularisation
Jones	2012	1. Incision 2. Incision with dressing 3. Incision, infection 4. Incision, infected, dressing	<i>L. fermentum</i> between tegaderms	Unknown	PB increased wound closure and histologically showed improved healing
Huseini	2012	1. Burn 2. Burn/base gel 3. Burn/SD 4. Burn/kefir 24 hours extract 5. Burn/kefir 48 hours extract 6. Burn/kefir 96 hours extract	Extract from kefir grains at different time points	Unknown	Kefir gel improved healing directly related to extract length and all better than SD
Partlow	2016	1. Wound 2. Wound/PB	<i>S. bouladrii</i>	5 billion once	No improvement with healing or microbiome
Argenta	2016	1. Burns 2. Burns/PB 3. Burns/PA 4. Burns/PA/PB	<i>L. plantarum</i>	1×10^9 CFU daily to wound	Burns/PA/PB had decreased mortality versus Burn/PA. PB decreased septicaemia and production of inflammatory markers
Satish	2017	1. Burn 2. Burn/PB 3. Burn/PA 4. Burn/PB then PA	<i>L. plantarum</i>	3×10^8 CFU daily	PB decreased severity and length of infection, improved collagen concentration
Oryan	2018	1. Burn 2. Burn/SD 3. Burn/PB/SD	Unclear	Unclear	Kefir decreased inflammatory markers, stimulated wound healing, angiogenesis, wound contraction migration of fibroblasts, fibrous connective tissue formation
Oryan	2018	1. Burn 2. Burn/SD 3. Burn/PB 4. Burn/collagen 5. Burn/PB/collagen	<i>S. cerevisiae</i>	10^7 CFU/mL every 5 days for 22 day	PB/collagen had best wound healing measured numerous ways
Ong	2019	1. Wound/SA/ointment 2. Wound/SA/PB	<i>L. plantarum</i> protein rich fraction	10% in ointment	PB inhibited <i>S. aureus</i> growth, enhanced cytokines and chemokines, wound contraction, keratinocyte migration

Abbreviations: Abx, antibiotics; BSA, body surface area; BT, bacterial translocation; Glu, glutamine; IMG, Imiquimod; PA, *P. aeruginosa*; PB, probiotic; SA, *S. aureus*; SD, silver sulfadiazine.

positive wound-healing environment.^{59–62} In contrast, topical insults are known to reduce AMP levels, thereby inhibiting wound healing.⁶³ However, some

commensal bacterial strains are able to produce their own AMPs, which can influence the production of human AMPs and act synergistically in wound healing

TABLE 2 Probiotics in wound healing: Human studies

Author	Year	Type of study	Level of evidence	Probiotic used	Dose	Patient population	Control	Finding
Peral	2009	RCT	II	<i>L. plantarum</i>	10 ⁵ daily to wound bed	Infected 2nd- and 3rd-degree burns, non-infected 3rd-degree burns	Silver sulfadiazine	<ol style="list-style-type: none"> 1. Non-infected 3rd-degree: no impact 2. Infected 2nd-degree: as effective as SD-Ag in decreasing bacteria load, promoting granulation and healing 3. Infected 3rd-degree: likely significantly improved healing if larger sample size
Peral	2010	Pilot study	III	<i>L. plantarum</i>	10 ⁵ daily to wound bed	Chronic venous ulcer	No control	PB reduced bacterial load, increased immune cells, modified inflammatory production, increased healing <i>Analysed cells from ulcer bed and compared with diabetics without ulcers and healthy subjects</i>
Zoccali	2016	Pilot	III	Probiotic derived active principles	Unknown	CO ₂ laser	Historical controls	PB reduced erythema and oedema duration
Twetman	2018	RCT	II	<i>L. reuteri</i>	5 × 10 ⁸ for 8 days BID prior and after in lozenge	Oral mucosa punch biopsy	Control lozenge	PB did not impact matrix metalloproteinases and interferons within 1 week
DiMarzio	1999	RCT	II	<i>S. thermophiles</i>	Unknown dose, 0.5 g, BID for 7 days	Non-pathologic	Lotion	PB increased skin ceramides
DiMarzio	2008	Pilot study	III	<i>S. thermophiles</i> BID	1.7 g/5 mL in 20 mL lotion BID	Elderly	Lotion	Increase in ceramides, hydration

Abbreviations: AD, atopic dermatitis; BSA, body surface area; LOS, length of stay; PB, probiotic; RCT, randomised control trial; SA, *S. aureus*.

and protective against pathogenic bacteria such as *S. aureus*^{14,15,64-69,70}.

Topical probiotic therapy has been explored in animal and human models of cutaneous injury with the primary aim of reducing infection to augment healing. In animal thermal injury models, topical probiotics and kefir were

able to decrease the production of inflammatory markers and associated septicaemia in infected wounds.^{37,71} In an infected animal wound model, probiotics were able to enhance the immune response.³⁹ In human burn patients, topical probiotics were able to decrease the bacterial load as effectively as silver sulfadiazine, as well as

result in a more favourable inflammatory response in patients with chronic venous ulcers^{40,41} (Tables 1 and 2).

4 | WOUND HEALING AND TOPICAL PROBIOTIC: PREVENTION AND TREATMENT OF BIOFILMS

It is estimated that up to 80% of human infections, especially chronic wounds, are associated with biofilms and impaired healing.^{72,73} Biofilm-associated cutaneous diseases include burns, pressure ulcers, surgical site infections, and diabetic foot ulcers. Studies have demonstrated that biofilms can include up to 20 genera of bacteria and 60 different subtypes.^{57,74} Once a biofilm has formed, it is nearly impossible to eradicate because of increased resistance to systemic antimicrobial treatments. Biofilm resistance has been estimated to be 100 to 1000 times greater than planktonic bacteria.⁷⁵⁻⁷⁷ When biofilms are exposed to sub-inhibitory antibiotic concentrations, or to the wrong antibiotics, mucoid phenotypes can develop, which generate thicker biofilms with additional matrix components, making eradication even more challenging.⁷⁸⁻⁸⁰ Thus, topical and oral antibiotics are often ineffective and can actually worsen the infection as they are unable to attack the biofilm and inherently disrupt native, protective bacteria. *In vitro* studies have shown that, in biofilms, distinct species antagonism occurs between pathogenic and “commensal” species, highlighting the importance of beneficial bacteria.¹⁸ It has been shown *in vitro* that the addition of probiotics to pathogenic bacterial cultures can inhibit the formation of biofilm development by pathogenic bacteria and fungi by about 50%.⁸¹

5 | WOUND HEALING AND TOPICAL PROBIOTIC: NON-PATHOLOGIC

Topical probiotics have also shown efficacy in healthy subjects. They were able to reduce the erythema and oedema associated with CO₂ laser therapy, reduce skin sensitivity in patients with reactive skin, and increase ceramide concentration and skin hydration.⁸²⁻⁸⁵ However, not all studies investigating topical probiotics have demonstrated superiority compared with traditional interventions^{43,44} (Table 2).

6 | CONCLUSION

Topical probiotics have demonstrated efficacy in multiple human and animal models at augmenting numerous

aspects of wound healing, but there are many unanswered questions. There is marked heterogeneity regarding the insult investigated, type and dosing regimen of the probiotic utilized, and a lack of standardized outcome measures. We hope this review will stimulate the initiation of well-conducted prospective studies to determine the role that topical probiotics could play in allowing for efficient, safe, and reproducible wound healing, as well as prompt potential clinical trials.

ORCID

Rebecca Knackstedt  <https://orcid.org/0000-0003-0961-4378>

REFERENCES

- Guarner F, Malagelada JR. Gut flora in health and disease. *Lancet*. 2003;361(9356):512-519.
- Quigley EM. Gut bacteria in health and disease. *Gastroenterol Hepatol (N Y)*. 2013;9(9):560-569.
- Shimizu K, Ogura H, Asahara T, et al. Gut microbiota and environment in patients with major burns—a preliminary report. *Burns*. 2015;41(3):e28-e33.
- Earley ZM, Akhtar S, Green SJ, et al. Burn injury alters the intestinal microbiome and increases gut permeability and bacterial translocation. *PLoS One*. 2015;10(7):e0129996.
- Wang F, Li Q, He Q, et al. Temporal variations of the ileal microbiota in intestinal ischemia and reperfusion. *Shock*. 2013;39(1):96-103.
- Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. *Science*. 2015;350(6262):830-834.
- Foster JA, Rinaman L, Cryan JF. Stress & the gut-brain axis: regulation by the microbiome. *Neurobiol Stress*. 2017;7:124-136.
- Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. *Nature*. 2016;535(7610):56-64.
- David LA, Materna AC, Friedman J, et al. Host lifestyle affects human microbiota on daily timescales. *Genome Biol*. 2014;15(7):R89.
- Haak BW, Levi M, Wiersinga WJ. Microbiota-targeted therapies on the intensive care unit. *Curr Opin Crit Care*. 2017;23(2):167-174.
- Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin microbiome. *Science*. 2009;324(5931):1190-1192.
- Kong HH, Segre JA. Skin microbiome: looking back to move forward. *J Invest Dermatol*. 2012;132(3 Pt 2):933-939.
- Lai Y, di Nardo A, Nakatsuji T, et al. Commensal bacteria regulate toll-like receptor 3-dependent inflammation after skin injury. *Nat Med*. 2009;15(12):1377-1382.
- Naik S, Bouladoux N, Linehan JL, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. *Nature*. 2015;520(7545):104-108.
- Naik S, Bouladoux N, Wilhelm C, et al. Compartmentalized control of skin immunity by resident commensals. *Science*. 2012;337(6098):1115-1119.
- Laborel-Preneron E, Bianchi P, Boralevi F, et al. Effects of the *Staphylococcus aureus* and *Staphylococcus epidermidis* secretomes

- isolated from the skin microbiota of atopic children on CD4+ T cell activation. *PLoS One*. 2015;10(10):e0141067.
17. Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. *J Invest Dermatol*. 2011;131(10):1974-1980.
 18. Malic S, Hill KE, Playle R, Thomas DW, Williams DW. In vitro interaction of chronic wound bacteria in biofilms. *J Wound Care*. 2011;20(12):569-570. 572, 574-7.
 19. Gan BS, Kim J, Reid G, Cadieux P, Howard JC. *Lactobacillus fermentum* RC-14 inhibits *Staphylococcus aureus* infection of surgical implants in rats. *J Infect Dis*. 2002;185(9):1369-1372.
 20. Thomson CH. Biofilms: do they affect wound healing? *Int Wound J*. 2011;8(1):63-67.
 21. Skonieczna-Zydecka K, Kaczmarczyk M, Łoniewski I, et al. A systematic review, meta-analysis, and meta-regression evaluating the efficacy and mechanisms of action of probiotics and synbiotics in the prevention of surgical site infections and surgery-related complications. *J Clin Med*. 2018;7(12):376-384.
 22. Mohseni S, Bayani M, Bahmani F, et al. The beneficial effects of probiotic administration on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial. *Diabetes Metab Res Rev*. 2018;34(3).
 23. Briat F, le Lay A, Dumas ME, Gauguier D. Implication of gut microbiota metabolites in cardiovascular and metabolic diseases. *Cell Mol Life Sci*. 2018;75(21):3977-3990.
 24. Marlicz W, Yung DE, Skonieczna-Zydecka K, et al. From clinical uncertainties to precision medicine: the emerging role of the gut barrier and microbiome in small bowel functional diseases. *Expert Rev Gastroenterol Hepatol*. 2017;11(10):961-978.
 25. Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in systemic inflammatory disease. *BMJ*. 2018;360:j5145.
 26. Wu XD, Liu MM, Liang X, Hu N, Huang W. Effects of perioperative supplementation with pro-/synbiotics on clinical outcomes in surgical patients: a meta-analysis with trial sequential analysis of randomized controlled trials. *Clin Nutr*. 2018;37(2):505-515.
 27. Chouraqui JP, Grathwohl D, Labaune JM, et al. Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or prebiotics and prebiotics in a randomized controlled trial. *Am J Clin Nutr*. 2008;87(5):1365-1373.
 28. Tapiovaara L, Lehtoranta L, Poussa T, Mäkivuokko H, Korpela R, Pitkäranta A. Absence of adverse events in healthy individuals using probiotics—analysis of six randomised studies by one study group. *Benef Microbes*. 2016;7(2):161-169.
 29. Petersen EBM, Skov L, Thyssen J, Jensen P. Role of the gut microbiota in atopic dermatitis: a systematic review. *Acta Derm Venereol*. 2019;99(1):5-11.
 30. Marcinkowska M, Zagórska A, Fajkis N, Kołaczkowski M, Paśko P. A review of probiotic supplementation and feasibility of topical application for the treatment of pediatric atopic dermatitis. *Curr Pharm Biotechnol*. 2018;19(10):827-838.
 31. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. *Dermatol Ther*. 2019; e12840.
 32. Tsiouris CG, Kelesi M, Vasilopoulos G, Kalemikerakis I, Papageorgiou EG. The efficacy of probiotics as pharmacological treatment of cutaneous wounds: meta-analysis of animal studies. *Eur J Pharm Sci*. 2017;104:230-239.
 33. Valdez JC, Peral MC, Rachid M, Santana M, Perdigon G. Interference of *Lactobacillus plantarum* with *Pseudomonas aeruginosa* in vitro and in infected burns: the potential use of probiotics in wound treatment. *Clin Microbiol Infect*. 2005;11(6):472-479.
 34. Rodrigues KL, Caputo LRG, Carvalho JCT, Evangelista J, Schneedorf JM. Antimicrobial and healing activity of kefir and kefir extract. *Int J Antimicrob Agents*. 2005;25(5):404-408.
 35. Jones M, Ganopolsky JG, Labbé A, et al. Novel nitric oxide producing probiotic wound healing patch: preparation and in vivo analysis in a New Zealand white rabbit model of ischaemic and infected wounds. *Int Wound J*. 2012;9(3):330-343.
 36. Huseini HF, Rahimzadeh G, Fazeli MR, Mehrzama M, Salehi M. Evaluation of wound healing activities of kefir products. *Burns*. 2012;38(5):719-723.
 37. Oryan A, Alemzadeh E, Eskandari MH. Kefir accelerates burn wound healing through inducing fibroblast cell migration in vitro and modulating the expression of IL-1ss, TGF-ss1, and bFGF genes in vivo. *Probiotics Antimicrob Proteins*. 2018: 874-886.
 38. Oryan A, Jalili M, Kamali A, Nikahval B. The concurrent use of probiotic microorganism and collagen hydrogel/scaffold enhances burn wound healing: an in vivo evaluation. *Burns*. 2018;44(7):1775-1786.
 39. Ong JS, Taylor TD, Yong CC, et al. *Lactobacillus plantarum* USM8613 aids in wound healing and suppresses *Staphylococcus aureus* infection at wound sites. *Probiotics Antimicrob Proteins*. 2019:125-137.
 40. Peral MC, Martinez MA, Valdez JC. Bacteriotherapy with *Lactobacillus plantarum* in burns. *Int Wound J*. 2009;6(1):73-81.
 41. Peral MC, Rachid MM, Gobbato NM, Martinez MAH, Valdez JC. Interleukin-8 production by polymorphonuclear leukocytes from patients with chronic infected leg ulcers treated with *Lactobacillus plantarum*. *Clin Microbiol Infect*. 2010;16(3):281-286.
 42. Satish L, Gallo PH, Johnson S, Yates CC, Kathju S. Local probiotic therapy with *Lactobacillus plantarum* mitigates scar formation in rabbits after burn injury and infection. *Surg Infect (Larchmt)*. 2017;18(2):119-127.
 43. Partlow J, Blikslager A, Matthews C, et al. Effect of topically applied *Saccharomyces boulardii* on the healing of acute porcine wounds: a preliminary study. *BMC Res Notes*. 2016;9:210.
 44. Twetman S, Pedersen AML, Yucel-Lindberg T. Probiotic supplements containing *Lactobacillus reuteri* does not affect the levels of matrix metalloproteinases and interferons in oral wound healing. *BMC Res Notes*. 2018;11(1):759.
 45. Robson MC. Wound infection. A failure of wound healing caused by an imbalance of bacteria. *Surg Clin North Am*. 1997;77(3):637-650.
 46. Bankey P, Fiegel V, Singh R, Knighton D, Cerra F. Hypoxia and endotoxin induce macrophage-mediated suppression of fibroblast proliferation. *J Trauma*. 1989;29(7):972-979. discussion 979-80.
 47. Murphy PS, Evans GR. Advances in wound healing: a review of current wound healing products. *Plast Surg Int*. 2012;2012: 190436.

48. Moberg S, Hoffman L, Ml G, Holst A. A randomized trial of cadexomer iodine in decubitus ulcers. *J Am Geriatr Soc.* 1983; 31(8):462-465.
49. Warriner R, Burrell R. Infection and the chronic wound: a focus on silver. *Adv Skin Wound Care.* 2005;18(Suppl 1): 2-12.
50. Miller AC, Rashid RM, Falzon L, Elamin EM, Zehtabchi S. Silver sulfadiazine for the treatment of partial-thickness burns and venous stasis ulcers. *J Am Acad Dermatol.* 2012;66(5):e159-e165.
51. Skog E, Arnesjö B, Troeng T, et al. A randomized trial comparing cadexomer iodine and standard treatment in the outpatient management of chronic venous ulcers. *Br J Dermatol.* 1983;109(1):77-83.
52. Draelos ZD, Rizer RL, Trookman NS. A comparison of post-procedural wound care treatments: do antibiotic-based ointments improve outcomes? *J Am Acad Dermatol.* 2011;64(3) Suppl:S23-S29.
53. Taylor SC, Averyhart AN, Heath CR. Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: a comparison of a skin protectant ointment and a topical antibiotic. *J Am Acad Dermatol.* 2011;64(3) Suppl:S30-S35.
54. Sullivan A, Nord CE. Probiotics in human infections. *J Antimicrob Chemother.* 2002;50(5):625-627.
55. Foligne B, Dewulf J, Breton J, Claisse O, Lonvaud-Funel A, Pot B. Probiotic properties of non-conventional lactic acid bacteria: immunomodulation by *Oenococcus oeni*. *Int J Food Microbiol.* 2010;140(2-3):136-145.
56. Nayak BS, Marshall JR, Isitor G. Wound healing potential of ethanolic extract of *Kalanchoe pinnata* lam. leaf—a preliminary study. *Indian J Exp Biol.* 2010;48(6):572-576.
57. Percival SL, Emanuel C, Cutting KF, Williams DW. Microbiology of the skin and the role of biofilms in infection. *Int Wound J.* 2012;9(1):14-32.
58. Roth RR, James WD. Microbial ecology of the skin. *Annu Rev Microbiol.* 1988;42:441-464.
59. Mangoni ML, McDermott AM, Zasloff M. Antimicrobial peptides and wound healing: biological and therapeutic considerations. *Exp Dermatol.* 2016;25(3):167-173.
60. Herman A, Herman AP. Antimicrobial peptides activity in the skin. *Skin Res Technol.* 2019;25(2):111-117.
61. Otvos L Jr, Ostorhazi E. Therapeutic utility of antibacterial peptides in wound healing. *Expert Rev Anti Infect Ther.* 2015;13(7):871-881.
62. Steinstraesser L, Koehler T, Jacobsen F, et al. Host defense peptides in wound healing. *Mol Med.* 2008;14(7-8):528-537.
63. Milner SM, Ortega MR. Reduced antimicrobial peptide expression in human burn wounds. *Burns.* 1999;25(5):411-413.
64. Lai Y, Cogen AL, Radek KA, et al. Activation of TLR2 by a small molecule produced by *Staphylococcus epidermidis* increases antimicrobial defense against bacterial skin infections. *J Invest Dermatol.* 2010;130(9):2211-2221.
65. Wanke I, Steffen H, Christ C, et al. Skin commensals amplify the innate immune response to pathogens by activation of distinct signaling pathways. *J Invest Dermatol.* 2011;131(2): 382-390.
66. Li D, Lei H, Li Z, Li H, Wang Y, Lai Y. A novel lipopeptide from skin commensal activates TLR2/CD36-p38 MAPK signaling to increase antibacterial defense against bacterial infection. *PLoS One.* 2013;8(3):e58288.
67. Cogen AL, Yamasaki K, Muto J, et al. *Staphylococcus epidermidis* antimicrobial delta-toxin (phenol-soluble modulins-gamma) cooperates with host antimicrobial peptides to kill group a streptococcus. *PLoS One.* 2010;5(1): e8557.
68. Cogen AL, Yamasaki K, Sanchez KM, et al. Selective antimicrobial action is provided by phenol-soluble modulins derived from *Staphylococcus epidermidis*, a normal resident of the skin. *J Invest Dermatol.* 2010;130(1):192-200.
69. Schommer NN, Gallo RL. Structure and function of the human skin microbiome. *Trends Microbiol.* 2013;21(12): 660-668.
70. Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against *Staphylococcus aureus* and are deficient in atopic dermatitis. *Sci Transl Med.* 2017;9(378):eaah4680.
71. Argenta A, Satish L, Gallo P, Liu F, Kathju S. Local application of probiotic bacteria prophylaxes against sepsis and death resulting from burn wound infection. *PLoS One.* 2016;11(10): e0165294.
72. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. *Annu Rev Microbiol.* 1995;49:711-745.
73. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. *Wound Repair Regen.* 2008;16(1):37-44.
74. Cowan T. Biofilms and their management: from concept to clinical reality. *J Wound Care.* 2011;20(5):220, 222-6-226.
75. Gilbert P, McBain AJ. Biofilms: their impact on health and their recalcitrance toward biocides. *Am J Infect Control.* 2001; 29(4):252-255.
76. Bayer AS, Speert DP, Park S, et al. Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of *Pseudomonas aeruginosa*. *Infect Immun.* 1991;59(1):302-308.
77. Thurlow LR, Hanke ML, Fritz T, et al. *Staphylococcus aureus* biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. *J Immunol.* 2011;186(11):6585-6596.
78. Kaplan JB. Antibiotic-induced biofilm formation. *Int J Artif Organs.* 2011;34(9):737-751.
79. Weiser J, Henke HA, Hector N, et al. Sub-inhibitory tigecycline concentrations induce extracellular matrix binding protein Embp dependent *Staphylococcus epidermidis* biofilm formation and immune evasion. *Int J Med Microbiol.* 2016;306(6):471-478.
80. Mlynek KD, Callahan MT, Shimkevitch AV, et al. Effects of low-dose amoxicillin on *Staphylococcus aureus* USA300 biofilms. *Antimicrob Agents Chemother.* 2016;60(5):2639-2651.
81. Hager CL, Isham N, Schrom KP, et al. Effects of a novel probiotic combination on pathogenic bacterial-fungal polymicrobial biofilms. *MBio.* 2019;10(2).
82. Di Marzio L, Cinque B, De Simone C, Cifone MG. Effect of the lactic acid bacterium *Streptococcus thermophilus* on ceramide levels in human keratinocytes in vitro and stratum corneum in vivo. *J Invest Dermatol.* 1999;113(1):98-106.
83. Di Marzio L, Cinque B, Cupelli F, De Simone C, Cifone MG, Giuliani M. Increase of skin-ceramide levels in aged subjects following a short-term topical application of bacterial

- sphingomyelinase from *Streptococcus thermophilus*. *Int J Immunopathol Pharmacol*. 2008;21(1):137-143.
84. Gueniche A, Bastien P, Ovigne JM, et al. *Bifidobacterium longum* lysate, a new ingredient for reactive skin. *Exp Dermatol*. 2010;19(8):e1-e8.
85. Zoccali G, Cinque B, la Torre C, et al. Improving the outcome of fractional CO₂ laser resurfacing using a probiotic skin cream: preliminary clinical evaluation. *Lasers Med Sci*. 2016;31(8):1607-1611.

How to cite this article: Knackstedt R, Knackstedt T, Gatherwright J. The role of topical probiotics on wound healing: A review of animal and human studies. *Int Wound J*. 2020;17:1687–1694. <https://doi.org/10.1111/iwj.13451>